The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Metformin monotherapy for type 2 diabetes mellitus
Abstract
BACKGROUND: Metformin is an anti-hyperglycaemic agent used for the treatment of type 2 diabetes mellitus. Type 2 diabetes may present long-term complications: micro- (retinopathy, nephropathy and neuropathy) and macrovascular (stroke, myocardial infarction and peripheral vascular disease). Two meta-analyses have been published before, although only secondary outcomes were assessed. OBJECTIVES: To assess the effects of metformin monotherapy on mortality, morbidity, quality of life, glycaemic control, body weight, lipid levels, blood pressure, insulinaemia, and albuminuria in patients with type 2 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from computerised searches of multiple electronic databases and hand searches of reference lists of relevant trials identified. Date of last search: September 2003. SELECTION CRITERIA: Trials fulfilling the following inclusion criteria: Diabetes mellitus type 2, metformin versus any other oral intervention, assessment of relevant clinical outcome measures, use of random allocation. DATA COLLECTION AND ANALYSIS: Two reviewers extracted data, using a standard data extraction form. Data were summarised under a random effects model. Dichotomous data were expressed as relative risk. We calculated the risk difference (RD), and the Number Needed to Treat, when it was possible. We collected data of mean and standard deviation from changes to baseline. However many trials reported end point data. This limitation lead to the expression of the results as standardised mean differences (SMD) and an overall SMD was calculated. Heterogeneity was tested for using the Z score and the I-squared statistic. Subgroup, sensitivity analysis and meta-regression were used to explore heterogeneity. MAIN RESULTS: We included for analysis 29 trials with 37 arms (5259 participants), comparing metformin (37 arms and 2007 participants) with sulphonylureas (13 and 1167), placebo (12 and 702), diet (three and 493), thiazolidinediones (three and 132), insulin (two and 439), meglitinides (two and 208), and glucosidase inhibitors (two and 111). Nine studies reported data on primary outcomes. Obese patients allocated to intensive blood glucose control with metformin showed a greater benefit than chlorpropamide, glibenclamide, or insulin for any diabetes-related outcomes (P = 0.009), and for all-cause mortality (P = 0.03). Obese participants assigned to intensive blood glucose control with metformin showed a greater benefit than overweight patients on conventional treatment for any diabetes-related outcomes (P = 0.004), diabetes-related death (P = 0.03), all-cause mortality (P = 0.01), and myocardial infarction (P = 0.02). Patients assigned to metformin monotherapy showed a significant benefit for glycaemia control, weight, dyslipidaemia, and diastolic blood pressure. Metformin presents a strong benefit for HbA1c when compared with placebo and diet; and a moderated benefit for: glycaemia control, LDL cholesterol, and BMI or weight when compared with sulphonylureas. AUTHORS' CONCLUSIONS: Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity, as it may prevent some vascular complications, and mortality. Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure. Sulphonylureas, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, and diet fail to show more benefit for glycaemia control, body weight, or lipids, than metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,094
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Self-citationMoher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Self-citationSystematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Statistical Methods for Rates and Proportions.
Plewis, I., & Fleiss, J. L. (1982) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2982107 · Cited by 1,731
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
(1970) · PubMed · Cited by 976
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
How study design affects outcomes in comparisons of therapy. I: Medical
Colditz, G. A., Miller, J. N., & Mosteller, F. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080408 · Cited by 520
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
1998 clinical practice guidelines for the management of diabetes in Canada
Meltzer, S. J., Leiter, L. A., Daneman, D., Gerstein, H. C., Lau, D. C. W., Ludwig, S. M., Yale, J., Zinman, B., Lillie, D., & Steering, C. (1998) · Canadian Medical Association Journal · Cited by 455
Cusi, K. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.11.4059 · Cited by 455
Chiasson, J.-L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., Ryan, E. A., Tan, M. H., & Wolever*, T. M. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00004 · Cited by 436
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
American Diabetes Association: clinical practice recommendations 1996.
(1996) · PubMed · Cited by 430
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Nagi, D. K., & Yudkin, J. S. (1993) · Diabetes Care · doi:10.2337/diacare.16.4.621 · Cited by 353
Hermann, L. S., Scherstén, B., Bitzén, P.-O., Kjellström, T., Lindgärde, F., & Melander, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.10.1100 · Cited by 344
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Moses, R., Slobodniuk, R., Boyages, S., Colagiuri, S., Kidson, W., Carter, J., Donnelly, T., Moffitt, P., & Hopkins, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.119 · Cited by 248
Horton, E. S., Clinkingbeard, C., Gatlin, M., Foley, J., Mallows, S., & Shen, S. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1660 · Cited by 241
Avilés-Santa, L., Sinding, J., & Raskin, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00004 · Cited by 225
Drewnowski, A. (1989) · Appetite · doi:10.1016/0195-6663(89)90017-2 · Cited by 208
Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy
Imano, E., Kanda, T., Nakatani, Y., Nishida, T., Arai, K., Motomura, M., Kajimoto, Y., Yamasaki, Y., & Hori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2135 · Cited by 196
Psaty, B. M. (1999) · JAMA · doi:10.1001/jama.282.8.786 · Cited by 187
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
Johansen, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.33 · Cited by 186
Grant, P. J. (1996) · Diabetes Care · doi:10.2337/diacare.19.1.64 · Cited by 173
Giugliano, D., Quatraro, A., Consoli, G., Minei, A., Ceriello, A., De Rosa, N., & D'Onofrio, F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315466 · Cited by 169
Charpentier, G., Fleury, F., Kabir, M., Vaur, L., & Halimi, S. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00582.x · Cited by 166
Hällsten, K., Virtanen, K. A., Lönnqvist, F., Sipilä, H., Oksanen, A., Viljanen, T., Rönnemaa, T., Viikari, J., Knuuti, J., & Nuutila, P. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3479 · Cited by 165
Some answers, more controversy, from UKPDS
Nathan, D. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)22937-0 · Cited by 164
Pavo, I., Jermendy, G., Varkonyi, T. T., Kerenyi, Z., Gyimesi, A., Shoustov, S., Shestakova, M., Herz, M., Johns, D., Schluchter, B. J., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021786 · Cited by 163
Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus
Scarpello, J. H. B., Hodgson, E., & Howlett, H. C. S. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199808)15:8<651::aid-dia628>3.0.co;2-a · Cited by 160
Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data
McCormack, J. P., & Greenhalgh, T. (2000) · BMJ · doi:10.1136/bmj.320.7251.1720 · Cited by 160
Johnson, A. B., Webster, J. M., Sum, C. F., Heseltine, L., Argyraki, M., Cooper, B. G., & Taylor, R. (1993) · Metabolism · doi:10.1016/0026-0495(93)90284-u · Cited by 154
Hoffmann, J., & Spengler, M. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00252-0 · Cited by 148
Robinson, A. C., Burke, J., Robinson, S., Johnston, D. G., & Elkeles, R. S. (1998) · Diabetes Care · doi:10.2337/diacare.21.5.701 · Cited by 146
Garber, A. J., Larsen, J. L., Schneider, S. H., Piper, B. A., Henry, D. A., & The Glyburide/Metformin Initial Therapy Study Group (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00211.x · Cited by 144
Ciaraldi, T. P., Kong, A. P. S., Chu, N. V., Kim, D. D. H., Baxi, S. C., Loviscach, M., Plodkowski, R. A., Reitz, R. E., Caulfield, M. P., Mudaliar, S. R. D., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.1.30 · Cited by 141
Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 121
Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes
Garber, A. J., Donovan, D. S., Dandona, P., BRUCE, S. R., & Park, J.-S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021225 · Cited by 120
Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
Nielsen, O. H., Schmitz, O., Andersen, P. H., Beck‐Nielsen, H., & Pedersen, O. B. (1989) · European Journal of Endocrinology · doi:10.1530/acta.0.1200257 · Cited by 118
Yu, J., Kruszynska, Y. T., Mulford, M. I., & Olefsky, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2414 · Cited by 110
Fisman, E. Z., Tenenbaum, A., Adler, Y., Motro, M., Boyko, V., Benderly, M., FRIEDENSOHN, A., Kohanovski, M., Rotzak, R., Schneider, H., et al. (2001) · Clinical Cardiology · doi:10.1002/clc.4960240210 · Cited by 107
Yale, J., Valiquett, T. R., Ghazzi, M. N., Owens-Grillo, J. K., Whitcomb, R. W., Foyt, H. L., & for the Troglitazone Triple-Therapy Study Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-9_part_1-200105010-00010 · Cited by 102
Chiasson, J., & Naditch‐Brûlé, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.989 · Cited by 100
Groop, L., Wid�n, E., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Schalin, C., & Eriksson, J. G. (1989) · Diabetologia · doi:10.1007/bf00285334 · Cited by 99
Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.
Prager, R., Schernthaner, G.-H., & Graf, H. (1986) · PubMed · Cited by 96
Antiatherogenic properties of metformin: the experimental evidence
Mamputu, J., Wiernsperger, N. F., & Renier, G. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72790-6 · Cited by 93
Marre, M., Howlett, H. C. S., Lehert, P., & Allavoine, T. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00774.x · Cited by 92
Clarke, B. F., & Campbell, I. W. (1977) · BMJ · doi:10.1136/bmj.2.6102.1576 · Cited by 91
Hermann, L. S., Scherstén, B., & Melander, A. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00253.x · Cited by 86
One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.
Campbell, I. W., Menzies, D. G., Chalmers, J., McBain, A. M., & Brown, I. R. F. (1994) · PubMed · Cited by 85
Tessier, D., Maheux, P., Khalil, A., & Fülöp, T. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90226-3 · Cited by 84
Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM Patients
Chan, J. C. N., Tomlinson, B., Critchley, J., Cockram, C. S., & Walden, R. (1993) · Diabetes Care · doi:10.2337/diacare.16.7.1035 · Cited by 81
What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes
Shaughnessy, A. F., & Slawson, D. C. (2003) · BMJ · doi:10.1136/bmj.327.7409.266 · Cited by 80
Amador‐Licona, N., Guízar-Mendoza, J., Vargas, E., Sánchez-Camargo, G., & Zamora-Mata, L. (2000) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00241-1 · Cited by 78
Willms, B., & Ruge, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00149.x · Cited by 77
The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 Diabetes
Rains, S. G. H., Wilson, G. A., Richmond, W., & Elkeles, R. S. (1988) · Diabetic Medicine · doi:10.1111/j.1464-5491.1988.tb01074.x · Cited by 76
Bayraktar, M., Thiel, D. H. V., & Adalar, N. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.252 · Cited by 75
Double-Blind Evaluation of Efficacy and Tolerability of Metformin in NIDDM
Dornan, T., Heller, S. R., Peck, G. M., & Tattersal, R. B. (1991) · Diabetes Care · doi:10.2337/diacare.14.4.342 · Cited by 73
Lalor, B., Bhatnagar, D., Winocour, P. H., Ishola, M., Arrol, S., Brading, M., & Durrington, P. N. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01378.x · Cited by 73
Blonde, L., Rosenstock, J., Mooradian, A. D., Piper, B. A., & Henry, D. A. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00229.x · Cited by 72
Sulphonylurea Failure in Type 2 Diabetes: Treatment with a Basal Insulin Supplement
Holman, R. R., Steemson, J., & Turner, R. C. (1987) · Diabetic Medicine · doi:10.1111/j.1464-5491.1987.tb00909.x · Cited by 72
Comparison of Tolbutamide and Metformin in Elderly Diabetic Patients
Josephkutty, S., & Potter, J. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01433.x · Cited by 71
Cefalu, W. T., Schneider, D. J., Carlson, H. E., Migdal, P., Lim, L. G., Izon, M. P., Kapoor, A., Bell–Farrow, A. D., Terry, J. G., & Sobel, B. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2123 · Cited by 71
The Diabetes Prevention Program and Its Global Implications
Molitch, M. E., Fujimoto, W. Y., Hamman, R. F., & Knowler, W. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000070140.62190.97 · Cited by 69
Abbasi, F., Kamath, V., Rizvi, A. A., Carantoni, M., Chen, Y. I., & Reaven, G. M. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1863 · Cited by 68
Goldstein, B. J., Pans, M., & Rubin, C. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80112-1 · Cited by 67
Tosi, F., Muggeo, M., Brun, E., Spiazzi, G., Perobelli, L., Zanolin, E., Gori, M., Coppini, A., & Moghetti, P. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00101-x · Cited by 66
Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
Ponssen, H., ELTE, J., Lehert, P., Schouten, J. P., & Bets, D. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)90005-5 · Cited by 64
Relimpio, F., Pumar, A., Losada, F., Mangas, M. Á., Acosta, D., & Astorga, R. (1998) · Diabetic Medicine · Cited by 63
Prager, R., & Schernthaner, G. (1983) · Diabetes · doi:10.2337/diab.32.12.1083 · Cited by 58
Gregorio, F., Ambrosi, F., Manfrini, S., Velussi, M., Carle, F., Testa, R., Merante, D., & Filipponi, P. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00201.x · Cited by 55
Collier, A., WATSON, H. H. K., Patrick, A. W., Ludlam, C. A., & Clarke, B. F. (1989) · PubMed · Cited by 55
Fanghänel, G., Sánchez‐Reyes, L., Trujillo, C., Sotres, D. A., & Espinosa-Campos, J. (1996) · Diabetes Care · doi:10.2337/diacare.19.11.1185 · Cited by 51
SCHNEIDER, J., Erren, T. C., Zöfel, P., & Kaffarnik, H. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90148-c · Cited by 51
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients
Tankova, T. I., Koev, D. J., Dakovska, L. N., & Кirilov, G. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00179-1 · Cited by 48
Comparison of Combined Therapies in Treatment of Secondary Failure to Glyburide
Trischitta, V., Italia, S., Mazzarino, S., Buscema, M., Rabuazzo, A. M., Sangiorgio, L., Squatrito, S., & Vigneri, R. (1992) · Diabetes Care · doi:10.2337/diacare.15.4.539 · Cited by 47
Rains, S. G. H., Wilson, G. A., Richmond, W., & Elkeles, R. S. (1989) · Journal of the Royal Society of Medicine · doi:10.1177/014107688908200213 · Cited by 47
Sundaresan, P., Lykos, D., Daher, A., Diamond, T., Morris, R., & Howes, L. G. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.692 · Cited by 43
Pedersen, O., Nielsen, O. H., Bak, J. F., Richelsen, B., Beck‐Nielsen, H., & Sørensen, N. S. (1989) · Diabetic Medicine · doi:10.1111/j.1464-5491.1989.tb01156.x · Cited by 42
Leptin and Body Fat in Type 2 Diabetes and Monodrug Therapy
Sivitz, W. I., Wayson, S. M., Bayless, M., Larson, L. F., Sinkey, C. A., Bar, R. S., & Haynes, W. G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021193 · Cited by 42
Noury, J., & Nandeuil, A. (1991) · PubMed · Cited by 39
Hermann, L. S., Karlsson, J. E., & Sj�strand, �. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315441 · Cited by 39
Uehara, M. H., Kohlmann, N. E. B., Zanella, M. T., & Ferreira, S. R. G. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00136.x · Cited by 38
Nagi, D., Mohamed‐Ali, V., & Yudkin, J. S. (1996) · Diabetic Medicine · Cited by 37
Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.
Marena, S., Tagliaferro, V., Montegrosso, G., Pagano, A., Scaglione, L., & Pagano, G. (1994) · PubMed · Cited by 37
Erle, G., Lovise, S., Stocchiero, C., Lora, L., Coppini, A., Marchetti, P., & Merante, D. (1999) · Acta Diabetologica · doi:10.1007/s005920050146 · Cited by 36
The insulin-sparing effect of metformin in insulin-treated diabetic patients
Golay, A., Guillet-Dauphiné, N., Fendel, A., Juges, C., & Assal, J. P. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110510 · Cited by 36
Intensive insulin therapy combined with metformin in obese type 2 diabetec patients
Fritsche, A., Schmülling, R.-M., Häring, H., & Stümvoll, M. (2000) · Acta Diabetologica · doi:10.1007/s005920070030 · Cited by 33
Donahue, S., Turner, K. C., & Patel, S. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241150-00004 · Cited by 32
Calle‐Pascual, A. L., Garcia-Honduvilla, J., Martin-Alvarez, P. J., Vara, E., Calle, J. R., Munguira, M. E., & Marañes, J. P. (1995) · PubMed · Cited by 31
Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger, N. W., Chiasson, J. L., Josse, R. G., Hunt, J. A., Palmason, C., Ross, S. A., Ryan, E., Tan, M., & Wolever, T. M. S. (1995) · PubMed · Cited by 29
Metformin added to insulin therapy in poorly controlled type 2 diabetes.
Hirsch, I. B. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.854b · Cited by 28
Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients
Prato, S. D., Erkelens, D. W., & Leuténegger, M. (2003) · Acta Diabetologica · doi:10.1007/s005920300004 · Cited by 27
Trischitta, V., Italia, S., Raimondo, M., Guardabasso, V., Licciardello, C., Runello, F., Mazzarino, S., Sangiorgi, L., Anello, M., & Vigneri, R. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03348039 · Cited by 27
The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action
Ohnhaus, E. E., Berger, W., Duckert, F., & Oesch, F. (1983) · Journal of Molecular Medicine · doi:10.1007/bf01537460 · Cited by 27
Groop, L., & Widén, E. (1991) · PubMed · Cited by 27
Garber, A. J., Marre, M., Blonde, L., Allavoine, T., Howlett, H. C. S., Lehert, P., & Cornes, M. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00259.x · Cited by 26
Damsbo, P., Hermann, L. S., Vaag, A. A., Nielsen, O. H., & Beck‐Nielsen, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1489 · Cited by 26
Hermann, L. S., Bitzén, P. ‐., Kjellström, T., Lindgärde, F., & Scherstén, B. (1991) · PubMed · Cited by 25
Acarbose for the treatment of Type II diabetes: the results of a Canadian multi-centre trial
Josse, R. G. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01081-n · Cited by 25
Teupe, B., & Bergis, K. (1991) · PubMed · Cited by 24
Hermann, L. S., Kjellström, T., & Nilsson‐Ehle, P. (1991) · PubMed · Cited by 22
Vigneri, R., Trischitta, V., Italia, S., Mazzarino, S., Rabuazzo, A. M., & Squatrito, S. (1991) · PubMed · Cited by 21
Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus.
Schneider, J. E. (1991) · PubMed · Cited by 21
McAlpine, L. G., McAlpine, C., Waclawski, E., Storer, A., Kay, J., & Frier, B. M. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00614548 · Cited by 20
Wolever, T. M. S., Assiff, L., Basu, T. K., Chiasson, J., Boctor, M., Gerstein, H. C., Hunt, J. A., Josse, R. G., Lau, D. C. W., Leiter, L. A., et al. (2000) · Nutrition Research · doi:10.1016/s0271-5317(00)80025-1 · Cited by 19
Garber, A. J., BRUCE, S. R., & Fiedorek, F. T. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80044-3 · Cited by 19
Johansen, K. B. (1984) · PubMed · Cited by 19
DOUBLE‐BLIND TRIAL OF METFORMIN IN THE THERAPY OF NONKETOTIC DIABETICS
Higginbotham, L., & Martin, F. I. R. (1979) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1979.tb134534.x · Cited by 19
A comparison of phenformin and metformin in the treatment of maturity onset diabetes.
Cairns, S., Shalet, S. M., Marshall, A. J., & Hartog, M. (1977) · PubMed · Cited by 17
Efficacy of low-dose metformin in Japanese patients with type 2 diabetes mellitus
Ohmura, C., Tanaka, Y., Mitsuhashi, N., Atsum, Y., Matsuoka, K., Onuma, T., & Kawamori, R. (1998) · Current Therapeutic Research · doi:10.1016/s0011-393x(98)85054-6 · Cited by 17
METFORMIN COMPARED WITH TOLBUTAMIDE IN THE TREATMENT OF MATURITY‐ONSET DIABETES MELLITUS
Lim, P., & Khoo, O. T. (1970) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1970.tb77850.x · Cited by 17
Boyd, K., Rogers, C., Boreham, C. A. G., Andrews, W. J., & Hadden, D. R. (1992) · PubMed · Cited by 16
Tessari, P., Biolo, G., Bruttomesso, D., Inchiostro, S., Panebianco, G., Vedovato, M., Fongher, C., & Tiengo, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989455 · Cited by 15
Wilson, J., Scott, M., & Gray, R. E. (1989) · Hormone and Metabolic Research · doi:10.1055/s-2007-1009224 · Cited by 15
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Jk, K., Pearce, K. A., Michielutte, R., & Summerson, J. H. (1999) · PubMed · Cited by 15
Rs, E. (1991) · PubMed · Cited by 15
Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment.
Silva, S. R. D., Betteridge, D. J., Shawe, J. E., Cudworth, A. G., & Alberti, K. G. M. M. (1979) · PubMed · Cited by 14
Hermann, L. S., Ranstam, J., Vaaler, S., & Melander, A. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00034.x · Cited by 13
Raptis, A. E., Tountas, N. A., Yalouris, A., Halvatsiotis, P., & Raptis, S. A. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979135 · Cited by 11
Niazi, R., & Muzaffar, Z. (1998) · PubMed · Cited by 11
METFORMIN COMBINED WITH CHLORPROPAMIDE IN THE TREATMENT OF DIABETES MELLITUS.
Bingle, J. P., & JAMES, J. L. (1964) · PubMed · Cited by 9
Insulin and sulphonylurea in the therapy of type 2 diabetes
Sotaniemi, E. A., VIERIMAA, E., Huupponen, R., Karvonen, I., Vuoti, M. J., & Rytömaa, K. (1990) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(90)90123-b · Cited by 8
Leblanc, H., Marre, M., Billault, B., & Passa, P. (1987) · PubMed · Cited by 7
[Treatment of obese diabetic patients using glucophage retard].
Munk, W. (1975) · PubMed · Cited by 6
Pérez, H. E. T., de Ossio, M. D. G., & Martínez, I. B. I. (1997) · Medicina Interna de México · Cited by 2
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Lee, Y. S., Kim, W. S., Kim, K. H., Yoon, M. J., Cho, H. J., Shen, Y., Ye, J.-M., Lee, C. H., Oh, W. K., Kim, C. T., et al. (2006) · Diabetes · doi:10.2337/db06-0006 · Cited by 1,054
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Mendis, S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.033647 · Cited by 487
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Metadata
- Authors
- Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2005-07-20
- Issue
- 3
- Pages
- CD002966-CD002966
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2129416530
- Cited by
- 308
- References
- 149
- Type
- reference entry
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.